Autonomix Medical, Inc. · NASDAQ:AMIX
Autonomix Medical — Reset Pharma — Investor Presentation (August 2023)
36 slides from Autonomix Medical's investor presentation, August 2023
Slide 1: Reset Pharma
Reset Pharma Treating Demoralization Syndrome to transform cancer treatment outcomes
Slide 2: Reset is developing the 1st treatment for the large Demoralization Syndrome market
Reset is developing the 1st treatment for the large Demoralization Syndrome (DS) market with a de-risked product & efficient path to commercialization Large market, high Late-Stage program Targeted commercial A unique, de-risked unmet need opportunity in the US opportunity • Filing IND Q3 2023 • >25
Slide 3: Victor Frankl quote
“Those who gave up on life, who had lost all hope for a future, were inevitably the first to die” Victor Frankl (Auschwitz survivor and author of ‘Man’s Search for Meaning’)
Slide 4: Demoralization Syndrome is often mis-diagnosed as Depression & treated with ADTs
Demoralization Syndrome is often mis-diagnosed as Depression & treated with ADTs* which have no effect Demoralization Depression1-3 Neurobiological syndrome1 underpinnings4 Can experience moments of Anhedonia, the inability to Morale in demoralization pleasure but overwhelming experience pleasure sy
Slide 5: Demoralization syndrome is a significant unaddressed challenge for >250,000 patients
Demoralization syndrome is a significant unaddressed challenge for >250,000 patients with cancer every year >1.9M >250k patients 0 approved Significantly people1 with cancer3 treatments3,4 increased3 will develop cancer will develop for Demoralization Risk of suicide in the US annually Demoralizatio
Slide 6: Once aware, providers are concerned about compliance and payers about value
Once aware, providers are concerned about impact on compliance and payers concerned about receiving value Oncologists estimate 15-30% of patients develop Demoralization Syndrome & are concerned with compliance Payers focused on cost containment given high cost of oncology treatments 1.https://www.ca
Slide 7: Reset Pharma
Reset Pharma Treating Demoralization Syndrome to transform cancer treatment outcomes 7
Slide 8: Reset Pharma in collaboration with NYU Langone Health
Reset Pharma in collaboration with NYU Langone Health Reset Pharma was founded on exclusively licensed data & intellectual property from NYU Langone Health that demonstrated a single dose of psilocybin delivered fast (24 hours) and sustained (4.5 years) clinical benefit in Demoralization Syndrome fo
Slide 9: Psilocybin demonstrated rapid & strong effect on Demoralization Syndrome in cancer
Psilocybin demonstrated rapid & strong effect (with high confidence) on Demoralization Syndrome in cancer Demoralization Hopelessness ** p<0.01 DEM – demoralization HAI – Hopelessness Assessment and Illness Ross et al, 2016 Study Design: Double-blind, placebo-controlled, crossover trial (after 7 wee
Slide 10: Effect maintained in Long Term follow-up
Effect maintained in Long Term follow-up Key Secondary endpoints showed sustained effect over time, n=14 subjects Note: This is a ‘survivor’ analysis and likely favors responders. Ref; Long-term follow-up of psilocybin-assisted psychotherapy for psychiatric and existential distress in patients with
Slide 11: Psilocybin studies demonstrate an attractive profile in patients with cancer
Psilocybin – studies demonstrate an attractive profile in patients with cancer who have Demoralization Syndrome Psilocybin Mode of Action 1, 2 5-HT2a agonist, 5-HT1a & 5-HT2c agonism & D2 agonism 1, 1 Nichols et al 2016, Tyls et al 2014 2 Sakashita et al, 2015 Unique profile • Single dose treatment •
Slide 12: Psilocybin showed similar sustained impact in patients with AIDS with Demoralization Syndrome
Psilocybin demonstrated similar, sustained clinical impact in patients with AIDS who had Demoralization Syndrome (n=18) (Anderson et al., 2020, Open label study with 18 patients, single dose of Psilocybin (0.3-0.36 mg/kg) accompanied by Psychotherapy) 12
Slide 13: Psilocin increases Dopamine in the Nucleus Accumbens impacting morale
Psilocin increases Dopamine in the Nucleus Accumbens impacting morale but does not increase Serotonin possibly explaining why SSRI’s have no impact on Demoralization Syndrome Nucleus Accumbens (Sakashita et al., 2015 Animal model (rats)) 13
Slide 14: Psilocin increases Serotonin transmission in the Medial Prefrontal Cortex
Psilocin shown to increase Serotonin transmission in the Medial Prefrontal Cortex impacting regulation of mood but not morale Medial Prefrontal Cortex (Sakashita et al., 2015) 14
Slide 15: Following pre-IND meeting with FDA, Reset plans to file IND in Q3 2023
Following a successful pre-IND meeting with FDA, Reset plans to file an IND in Q3 2023 & move to Ph2b November 2021 Overview Area of focus Successful pre-IND Randomized, multicenter, Designed to identify the optimal meeting with FDA double-blind, parallel-group dose study designed to assess the of RS
Slide 16: Validated Demoralization Scale; Ph2b to confirm primary endpoint
Validated Demoralization Scale; Reset's Ph2b study will confirm primary endpoint to be used for pivotal Phase 3 program DEMORALIZATION SCALE For each statement below, please indicate how strongly you have felt this way over the last two weeks by circling the corresponding number. Never Seldom Sometim
Slide 17: Reset Pharma is building a strong, multiple layer IP portfolio
Reset Pharma is building a strong, multiple layer IP portfolio with potential for protection beyond 2040 Reset’s modeling shows the potential to optimize psilocybin and psilocybin-related product delivery to patients through targeted, proprietary formulations We are developing Reset has submitted 13
Slide 18: Market Research Summary
Market Research Summary Reset Pharma
Slide 19: Once aware of DS, HCPs estimate 10%-30% prevalence
Once aware of DS, HCP’s estimate 10%-30% prevalence & are concerned with cancer treatment compliance, reacting positively to RSTP-1000 Context • Cancer is recognized as having a profound impact on mental health, where providers observe many patients suffering from significant mental health impact bu
Slide 20: Reset Team
Reset Team Reset Pharma
Slide 21: We are CNS experts
We are CNS experts Reset Pharma boasts an experienced CNS leadership team 1 2 3 Our leadership team is comprised of We unite development and We have significant experience scientific and strategic professionals at commercialization expertise to successfully developing and the forefront of CNS R&D an
Slide 22: Leadership team
Leadership team Innes Meldrum Anne Andorn, Elissa Fuller Sue Learned, Satish Åsa Holmgren, Willi Stahl MD MD, PharmD, PhD Prabhu, CPA MScPharm PhD President / Chief Chief Business Executive Officer Chief Medical Head of Chief Financial Head of CMC Officer & GC Regulatory Affairs Officer R&D Officer Cop
Slide 23: Scientific advisory board
Scientific advisory board Gil Block, MD, PhD Harvey Max Chochinov, MD, Benjamin Kelmendi, MD PhD, FRSC Head Scientific Advisory Board Assistant Professor, Psychiatry at Distinguished Professor Psychiatry, Yale School of Medicine; University of Manitoba, Director of Assistant Chief, Clinical the Manit
Slide 24: Board members and strategic advisory board
Board members and strategic advisory board Founders + Board Members Strategic Advisory Board Philip Taub Steven Juelsgaard, DVM, JD Brad Sitko Founder, Chairman of the Board Secretary to Genentech Board 1997 - MD, Strategic Finance, RTW Founder and Managing Partner, 2009 Investments Evolution Ventur
Slide 25: Key achievements and Next Steps
Key achievements and Next Steps 25
Slide 26: Key achievements
Key achievements Exclusive License Agreement and Research Agreement with NYU Langone Health Closed Series A financing Q1 2021 led by Palo Santo Completed Pre-IND meeting with FDA Nov 2021 Experienced management team established Filed 13 patent applications to cover a wide range of aspects of treatme
Slide 27: Next Steps: major development milestones
Next Steps: major development milestones Late 2025/ 1Q 2024 3Q 2025 3Q 2023 early 2026 Q1 2026 2026 Phase-2b study Phase-2b study End of Phase 2 Selection of Single Phase 3 IND submission start (FPFV) completion Meeting with proprietary, pivotal study (LPLV) FDA and clinically start (FPFV) submissio
Slide 28: Investment history and budget
Investment history and budget Reset is raising $40M Reset Seed funding of to fund its Phase-2b has raised $2.6M (2020) study, continue development of Series A (Jan ’21) $11M of $8.4M proprietary formulation and continue to expand its IP portfolio Copyright © Reset Pharmaceuticals Inc. All rights Res
Slide 29: Executive Summary
Executive Summary Reset Pharma
Slide 30: Reset is developing the 1st treatment for the large Demoralization Syndrome market
Reset is developing the 1st treatment for the large Demoralization Syndrome (DS) market with a de-risked product & efficient path to commercialization A unique, de-risked Late-Stage program Targeted commercial Large market, opportunity opportunity in the US significant unmet need • Filing IND Q3 202
Slide 31: Thank you
Thank you Reset Pharma
Slide 32: Appendix
Appendix Reset Pharma
Slide 33: Reset is uniquely focused on establishing a new, profitable business model in oncology
Reset is uniquely focused on establishing a new, profitable business model in oncology ● Psychedelics require a new commercial business model to support single-treatment regimens ● Oncology is the largest area of focus for pharmaceutical companies ○ Will generate $250B in global sales in 2024 ○ Canc
Slide 34: Reset Pharma is uniquely positioned in oncology
Reset Pharma is uniquely positioned in oncology Points of Differentiation Reset Pharma Other Psychedelic Companies Disease area of focus Psych-oncology Psychiatry Indication Demoralization syndrome/not well established TRD/established Difficulty of treating Moderate (less neurologically entrenched)
Slide 35: Demoralization Syndrome already included in ICD-11 and DSM-5
Demoralization Syndrome already included in ICD-11 and DSM-5 ICD-11: MB22.2 Demoralization Description Loss of confidence in one's ability to cope, with associated feelings of helplessness, hopelessness, and discouragement. DSM-5-TR - Feb 2022 - Page 209 Demoralization is a common reaction to chroni
Slide 36: 3 studies in patients with cancer and depression showed similar fast, sustained impact
3 studies in patients with cancer and depression demonstrated similar fast, sustained impact when treated with Psilocybin Beck Depression Inventory Grob et al 2011 Ross et al 2016 Griffiths et al 2016 N=12 N=29 N=51 double-blind, placebo-controlled study of patients with Double-blind, placebo-contro